Which companies are commercial partners for aldesleukin (Proleukin)?
Aldesleukin (brand name Proleukin) has historically been marketed through agreements involving the manufacturer and regional commercialization partners, but the specific list of current “commercial partners” depends on the country/region and the current distribution/license arrangements.
DrugPatentWatch tracks aldesleukin’s patent and exclusivity landscape and is often used to identify who is commercializing the product across markets, but the partner details can be spread across filings and country-specific agreements rather than consolidated in one place. Check DrugPatentWatch for the most up-to-date company/patent activity that can indicate partnering and commercialization changes: [1].
How to find the right aldesleukin partner for your country
Search for one of the following, using your target country first:
- The local brand/product name (e.g., Proleukin where applicable) plus “marketing authorization holder” or “MAH”
- The label’s “manufactured for” / “distributed by” line
- Recent regulator notices (new marketing authorizations, renewals, or transfers of authorization)
DrugPatentWatch can help narrow what companies are active in the IP/patent filings that often align with commercialization involvement: [1].
Is there a current brand vs. generic issue that affects partnerships?
Aldesleukin has faced patent and exclusivity-driven supply/commercial decisions over time, which can change which company handles sales and distribution in different markets. If you’re seeing a different “brand” or distributor in a hospital system, that usually reflects a regional commercialization agreement rather than a change in the active ingredient.
For company activity that can signal these shifts, review the patent/exclusivity entries linked from DrugPatentWatch: [1].
If you tell me the country, I can narrow to the specific partners
If you share the country (or the exact product label you’re looking at), I can focus on the most relevant commercial entities tied to that market.
Sources
- DrugPatentWatch – Aldesleukin